Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Gustoeson Jan 16, 2015 9:15am
76 Views
Post# 23327060

RE:News

RE:News
Macer wrote: Same topic just not promoting responses to the clowns responses.

Very significant news in that they have now made a final decision on the PDC to move forward with into production. Production for both continued pre-clinical research on toxicology and human clinical trials.

Anyone ever heard of deals being inked at these conferences?
Two divisions (anti-cancer and therapuetic) should be plenty for this small company to chew on for the next few years. Especially if the anti-cancer takes off with human trials and alternate cancer targets. Would be a decent time to look at spinning off the anti-microbial side of the business.

Any idea of a possible suitor is also attending this conference?

Yes, you can call that a pump. But it is also my intuitiion speaking. Roger is very suave and he has been walking the walk lately. Something tells me he is working on something.

Macer



I wonder if there are examples of early bio deals that we could look at. Preclinical. Phase 1?
I suppose with my belief in the science and belief that human clinicals will be successful, I'd rather not see a deal this year. More value for shareholders if we prove the science first.
Bullboard Posts